The Influence of Obesity, Ovariectomy, and Greenshell Mussel Supplementation on Bone Mineral Density in Rats

Parkpoom Siriarchavatana,1,2 Marlena C Kruger,3,4 Matthew R Miller,5 Hong (Sabrina) Tian,6 and Frances M Wolber1,7

1School of Food and Advanced Technology, Massey University, Palmerston North, New Zealand
2Department of Pharmacology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand
3School of Health Sciences, Massey University, Palmerston North, New Zealand
4Riddet Centre of Research Excellence, Massey University, Palmerston North, New Zealand
5Cawthron Institute, Nelson, New Zealand
6Sanford Ltd., Auckland, New Zealand
7Centre for Metabolic Health Research, Massey University, Palmerston North, New Zealand

ABSTRACT
Obesity is considered to impair long-term health by disturbing multiple physiological functions. However, it remains a controversial issue as to whether obesity has beneficial or detrimental effects on bone health in postmenopausal women. The aims of this study were to investigate the relationships between obesity and bone mineral density (BMD) under conditions of ovarian hormone deficiency in an animal model and to evaluate the potential health benefits of Greenshell mussel (GSM) on bone health. A total of 144 adult female Sprague–Dawley rats were fed from age 12 weeks on one of four diets (normal [ND]; ND + GSM; high fat/high sugar [HF/HS]; HF/HS + GSM; n = 36 per diet). At age 20 weeks, after a dual-energy X-ray absorptiometry (DXA) scan, 12 of the rats on each diet underwent ovariectomy (OVX) and the remaining rats were left intact. Twelve of the intact rats in each diet group were culled at age 26 weeks (short-term cohort). The remaining rats were culled at age 48 weeks (long-term cohort). Rats were DXA scanned before cull, then various fat pads were dissected. The results revealed that HF/HS rats and OVX rats dramatically increased body weight and fat deposition in correlation with leptin. In the long-term cohort, vertebral spine BMD rapidly declined after OVX. At termination, the OVX rats had decreased plasma bone turnover markers of CTX-1 and TRAP when compared with sham rats. Significantly higher BMD was found in OVX rats fed the HF/HS diet compared with ND, but this difference was not recapitulated in intact rats. BMD of right femur was significantly increased 5% to 10% by GSM in the short-term cohort. The data demonstrated that obesity can be beneficial by increasing BMD in OVX rats, and this may extrapolate to postmenopausal women as adipocyte-produced estrogen may slightly compensate for the reduction in ovarian hormones. Finally, the data showed that GSM may be beneficial to bone health by increasing BMD accrual. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

KEY WORDS: BODY COMPOSITION; BONE MINERAL DENSITY; GREENSHELL MUSSEL; OBESITY

1. Introduction
The incidence of obesity has increased worldwide in the last five decades.1 It has been recognized as a predisposing cause for many chronic diseases, including hypercholesterolemia, hypertension, cardiac disease, and type 2 diabetes, giving it the status of a global public health burden.1 Osteoporosis is a disease of aging, and it shares a complex relationship with obesity. It used to be considered that obesity had a positive effect on osteoporosis based on a positive correlation between bone mineral density (BMD) and body mass index (BMI)2–4 and evidence from computed tomography showing that obese people have higher BMD in cortical and trabecular bone as well as increased trabecular bone at the distal radius and tibia.5,6 Further support from a meta-analysis study showed that low BMI correlated with hip fracture risk7 with obese adults having lower risk of hip fracture.8 Despite strong evidence of increased BMD in obese adults, the incidence of bone fracture is increased in obese children.9 Further, there is an increased fracture risk in obese people at the proximal humerus, upper legs, and ankles10,11 particularly in postmenopausal women.12 However,
the fracture risk in these bone sites might be attributed to impairment of muscular function causing instability of movement in obesity. Although obesity in older adults is accepted as being at least partly protective against osteoporosis, it is also clearly a risk factor for other chronic disorders, such as osteoarthritis, diabetes, cardiovascular disease, and metabolic syndrome. These contradictions in the benefits versus detriments of obesity have given rise to the term “obesity paradox.”

Homeostasis of bone is the equilibrium between bone formation supported by osteoblasts and bone remodeling driven by osteoclasts. From a perspective of cell origin, adipogenesis bias could threaten bone formation and result in bone loss because adipocytes and osteoblasts share a common precursor mesenchymal stem cell in bone marrow. This notion is evidenced by the fact that bone marrow of obese mice has more adipocyte infiltration. However, the increase of mechanical loading on bone in obesity can inhibit apoptosis and increase proliferation of osteoblasts and osteocytes by activation of the Wnt/β-catenin signaling pathways. This could result in an increase in bone formation.

Another controversial factor is leptin, a adipokine secreted from adipocytes, which is significantly increased in the blood of obese people. On one hand, leptin has osteogenic effects by increasing osteoblastogenesis and suppressing adipocytic differentiation in human marrow stromal cells. Strong evidence supports the role of leptin in increasing BMD. Stephan and colleagues demonstrated that leptin administration resulted in an increase in femoral bone length, bone mineral content, and BMD in leptin-deficient mice (ob/ob mice). Injection of leptin mitigated cancellous and trabecular bone loss in ovariectomized rats. However, other studies suggest that the effect of leptin on the central nervous system was different from its effect on peripheral tissues, resulting in the reduction of BMD. Moreover, leptin indirectly activates osteoclastogenesis by activating macrophages to produce pro-inflammatory cytokines. These cytokines in turn increase receptor activator of NF-κB ligand (RANKL) expression in osteoblasts, which directly activates the process of osteoclast differentiation and subsequent bone resorption. Finally, adipocytes in large numbers, as occurs in obesity, can themselves increase the pro-inflammatory cytokines TNF-α, IL6, IL1β, IFN-γ, MIP-1, GRO-α, and RANTES.

The relationship between obesity and BMD is further complicated under postmenopausal circumstances. Estrogen deficiency is associated with not only fat deposition but also bone loss, leading to osteoporosis. In addition to the lack of estrogen causing calcium loss from bone, parathyroid levels are elevated correlating with body weight in obese menopausal women, whereas circulating 25-hydroxyvitamin D levels are low in obese people. This evidence supports a correlation between bone loss and obesity in postmenopausal women. However, an increase in adiposity has a benefit on estrogen replacement because aromatase in adipocytes has the ability to produce estrogen as an alternative source for postmenopausal women. The controversy remains a highly debated subject and is unlikely to reach a consensus in clinical research. The current study addressed the issues described above by using an obese rat model compounded with the multiple challenges (high-fat/high-sugar diet, ovariectomy (OVX), metabolic dysregulation) and followed serial stages of the life cycles in order to further understand the changes in BMD in the context of obesity, postmenopause, and aging.

Supplements containing components of Greenshell mussel (GSM) have been widely reported to be a rich source of omega-3 fatty acids and to have beneficial anti-inflammatory and anti-arthritis effects. Omega-3 fatty acids have been shown to protect against osteoporosis, although there is no published information to date regarding any potential benefits of GSM on bone health. The current study assessed whether GSM could benefit bone health by increasing BMD in growing rats or reducing bone loss in ovariectomized rats under either normal or obese conditions. The findings from this study combined with additional studies using a rat model as a tool for preclinical studies assessing the effect of GSM on obesity-related disorders may clarify some of the ambiguities in the BMD-obesity relationship and as well as in the obesity paradox.

2. Materials and Methods

2.1 Greenshell mussel and diet composition analyses

Flash-dried powder from whole GSM meat was produced by Sanford Ltd (ENZAQ facility, Blenheim, New Zealand) using standard manufacturing processes and assessed for proximate composition in a commercial testing laboratory (Food Testing Laboratory of Cawthron Analytical Services, Nelson, New Zealand). To measure the stability of the diets, samples from each of the experimental diets used in the study were collected and frozen after mixing with mussel powder and the nutritive value analyzed according to the Association of Official Analytical Chemists (AOAC) methods for crude protein (AOAC 981.10), total fat (AOAC 948.15), moisture at 105°C (AOAC 950.46), and ash (AOAC 920.153). Carbohydrate content was determined by calculation (100% – % crude protein – % total fat – % moisture – % ash). An aliquot of the total lipid extract from the GSM powder was transmethylated in methanol/chloroform/hydrochloric acid (10:1:1, v/v/v) for 1 hour at 100°C. After the addition of water, the mixture was extracted three times with hexane/chloroform (4:1, v/v) to obtain fatty acid methyl esters (FAME). Samples were made up to 1 mL with an internal injection standard (19:0 FAME) and analyzed by gas chromatography mass spectrometry (GC-MS) according to AOAC 963.22.

2.2 Animals and study design

A total of 144 female Sprague–Dawley rats aged 12 weeks were obtained from the Small Animal Production Unit at Massey University (Palmerston North, New Zealand), randomized into groups, and fed test diets for 14 weeks (short-term cohort, 48 rats) or 36 weeks (long-term cohort, 96 rats) after a 1-week acclimatization period. Animals were maintained in conventional systems and singly housed in plastic “shoebox” cages with high-top wire lids, using heat-treated aspen wood shavings as bedding. The rat rooms were kept at 22 ± 1°C, 45% to 55% humidity, and a 12-hour light/dark cycle. The numbers of rats per test group were selected calculating a power (1-β) of 0.8 and a type 1 error rate (α) of 5% for the key parameter of BMD using data from our research group’s previous rat studies. All aspects of the study were approved by Massey University Animal Ethic Committee (MUAEC protocol/approval 16/112).

Normal versus high-fat/high-sugar diets were used to allow comparisons between normal-weight and obese rats groups that these diets generated. Each base diet type (Speciality Feeds, Glen Forrest, Western Australia) was obtained as a single batch, packaged in vacuum-sealed plastic pouches, and used within 9 months of receipt. Diets were stored frozen until needed. All diets were designed to contain 15% protein as is standard for
AIN-93M. The proportion of GSM was selected on the assumption that, extrapolated to the human diet, one meal out of each three meals per day would source the protein from GSM; therefore, for the rat diets, one-third of the protein was sourced from GSM for the GSM-containing diets. After thawing a pouch in the refrigerator, diets designed to incorporate GSM had GSM powder added in a ratio of one part GSM/nine parts base diet. Diets were then stored refrigerated during the week of use. Subsamples of each diet were taken periodically for further chemical analysis.

Each day, uneaten diet from each individual feeder was weighed and discarded, and feeders were cleaned and filled with new food, which was weighed and recorded to measure food intake. The test diets, designed to meet or exceed all AIN-93M requirements, were:

- normal control diet (ND) containing 5% total fat (from soy oil), 5% sucrose, and 15% total protein (from casein);
- normal control diet supplemented with GSM (ND + GSM) containing 5% total fat (84% from soy oil/16% from GSM), 5% sucrose, and 15% total protein (66% from casein/33% from GSM);
- high-fat/high-sugar diet (HFHS) containing 30% total fat (50% from soy oil/50% from lard), 30% sucrose, and 15% total protein (from casein);
- high-fat/high-sugar diet supplemented with GSM (HFHS + GSM) containing 30% total fat (49% from soy oil/49% from lard/1% from GSM), 30% sucrose, and 15% total protein (66% from casein/33% from GSM).

2.3 Dual-energy X-ray absorptiometry (DXA) scans

DXA whole-body and regional scans to generate BMD and fat mass/lean mass data in the short-term cohort were performed at baseline (age 12 weeks) and after 8 and 14 weeks on the experimental diets (age 20 and 26 weeks). The long-term cohort schedule was similar to the short-term cohort but with an additional scan after 36 weeks on the experimental diets (age 48 weeks). For both cohorts, after the baseline DXA scan, rats were randomized into diet groups, ensuring that there were no significant differences between groups in basal body weight and no significant differences in lumbar spine and whole-body bone mineral densities. Rats in the long-term cohort were further randomized into surgical groups within their diet groups, with randomization again based on eliminating significant differences in body weight and BMD.

Anesthesia and DXA scans were carried out as described previously. BMD was evaluated with a Hologic Discovery, a bone densitometer (Hologic Inc., Bedford, MA, USA). Quality-control checks were performed before scanning the animals, and the acceptance of coefficient of variance was 0.98 to 1.01. Rats were positioned supine with right angles between the spine and femurs. All scans used a high-resolution mode.

2.4 Surgical procedures and euthanasia

In the long-term cohort, at the age of 20 weeks, half of each group (12 of 24 rats) underwent ovariectomy and the other half a sham surgery as described previously. At the end of each cohort, all rats were subjected to euthanasia by undergoing deep anesthesia followed by exsanguination. Samples including different fat pads (inguinal fat, interscapular brown fat, retroperitoneal fat and perigonadal fat) were dissected and weighed.

2.5 Plasma analysis for leptin and bone biomarkers

At the end of the study, anesthetized rats underwent cardiac puncture. Blood was drawn and collected in EDTA-anticoagulant tubes. Plasma was separated by centrifugation at 2500 rpm (Herareus Megafuge 1.0R, Thermo Fisher Scientific, Waltham, MA, USA) and kept at −80 °C until analysis. All analytes were measured using ELISA kits except for tartrate-resistant acid phosphatase (TRAP), for which individual chemical reagents for a chromogenic assay performed as published elsewhere were purchased from Sigma-Aldrich (St. Louis, MO, USA). Leptin was measured using Quantikine Kits (R&D Systems, Minneapolis, MN, USA). CTX-I assay kits were obtained from Cloud-Clone Corp. (Houston, TX, USA). Samples were performed in duplicate, and reactions were measured using a microplate reader (Multiskan FC, Thermo Fisher Scientific, Vantaa, Finland).

2.6 Data analysis

Body weight, feed intake, and fat pads were analyzed by one-way ANOVA followed by the least significant difference test. Student’s t test was used to identify statistically significant differences in fat pad weights between the short-term rats and the sham rats in the long-term cohort or the sham rats and OVX rats. Data from serial DXA scans were analyzed by repeated measure method composed of three effects: diet (ND/HFHS), GSM (yes/no), and surgical procedure (OVX, sham). Pearson correlation was used to evaluate relationships between body composition and BMD. Bone markers in blood collected from the rats at termination were analyzed by two-way ANOVA. Statistical analysis was performed using IBM (Armonk, NY, USA) statistic software version 25, and differences were considered significant at p < 0.05.

3. Results

3.1 Analysis of diet composition

Protein was equivalent in all diets (Table 1), but the partial substitution of carbohydrate with fat in the HFHS and HFHS + GSM diets increased the energy levels to 24.9 and 22.9 kJ/g compared with the ND and ND + GSM diets (16.9 and 16.8 kJ/g, respectively). Added fat in the HFHS diet increased saturated fatty acid (SFA) and monounsaturated fatty acid (MUFA) but not polyunsaturated fatty acid (PUFA). Two important omega-3 fatty acids particularly associated with bone-health protection, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), were increased in diets containing GSM, but there was no change in the omega-6 fatty acids (linoleic acid and arachidonic acid) (Table 1). Ash content of GSM powder contains high amounts of inorganic substances, including sodium and calcium. Inclusion of GSM powder to the base diets resulted in an increase of 2% to 4% ash in those diets.

3.2 Body weight gain and food consumption

Time 0 (T0) designates the period of growing rats on standard chow from age 4 to 12 weeks, during which the rate of body weight (BW) gain of almost 3 g/d was similar across all groups in the long-term cohort (Fig. 1 [FIG1]and Table 2. [TBL2] The experimental diets were introduced to the animals at week 12 (the end of T0). At this stage, the range of mean BW across all groups was 267.37 to 280.84 g with no significant difference between groups (p = 0.911). The rate of mean BW gain in the
Table 1. Nutritive Value of the Four Different Diets in the Study

| Diet composition | ND         | ND + GSM   | HFHS       | HFHS + GSM |
|------------------|------------|------------|------------|------------|
| Proximate composition (g/100 g) |            |            |            |            |
| Fat              | 5.4        | 5.1        | 31.3       | 30.1       |
| Ash              | 2.9        | 4.7        | 2.7        | 4.1        |
| Moisture         | 8.3        | 8.2        | 3.7        | 3.3        |
| Crude protein    | 13.5       | 13.3       | 13.5       | 12.6       |
| Carbohydrate     | 69.9       | 68.7       | 48.8       | 49.9       |
| Fatty acid profile (% fatty acids) |            |            |            |            |
| C16:0 palmitic acid | 11.2      | 12.1       | 18.2       | 17.8       |
| C18:0 stearic acid | 4.8       | 4.7        | 10.4       | 10         |
| C18:1n7 vaccenic acid | 1.5      | 1.7        | 1.9        | 1.9        |
| C18:1n9 oleic acid | 21.9      | 20.6       | 28.2       | 27.8       |
| C18:2n6c linoleic acid | 48.6     | 45.5       | 31.7       | 31.6       |
| C18:3n3 alpha linolenic acid (ALA) | 6.2      | 5.8        | 4.1        | 4.2        |
| C20:4n6 arachidonic acid (AA) | <0.1     | <0.1       | <0.1       | <0.1       |
| C20:5n3 eicosapentaenoic acid (EPA) | <0.1      | 1.2        | <0.1       | 0.31       |
| C22:6n3 docosahexaenoic acid (DHA) | <0.1    | 0.93       | <0.1       | 0.21       |
| ∑SFA             | 16         | 16.8       | 28.6       | 27.8       |
| ∑MUFA            | 23.4       | 22.3       | 30.1       | 29.7       |
| ∑PUFA            | 54.8       | 53.43      | 35.8       | 36.32      |
| ∑n-3 PUFA        | 6.2        | 7.93       | 4.1        | 4.72       |
| ∑n-6 PUFA        | 48.6       | 45.5       | 31.7       | 31.6       |

ND = normal control diet; HFHS = high-fat/high-sugar diet; GSM = Greenshell mussel powder; ∑SFA = sum of saturated fatty acids; ∑MUFA = sum of monounsaturated fatty acids; ∑PUFA = sum of polyunsaturated fatty acids; ∑n-3 PUFA = omega-3 polyunsaturated fatty acids; ∑n-6 PUFA = omega-6 polyunsaturated fatty acids. Diet samples were taken during the experimental period and sent to Cawthron Institute at the end of the study. The analysis was performed according to the Association of Official Analytical Chemists (AOAC) methods.

Fig 1. Study plan and body weight (BW) gain in rats along the long-term cohort. Individual rat body weights were recorded in grams every week. Group mean ± SE are shown, plotted in the line graph. ND = normal control diet; HFHS = high-fat/high-sugar diet; OVX = ovariectomy; DXA = dual energy X-ray absorptiometry scanning. The periods of the study were specified as “Time”; Time 0 = rat growing period on standard chow; Time 1 = experimental diets provided for 8 weeks; Time 2 = 8 weeks after the surgical procedure; Time 3 = termination of the study.
Table 2. Changes in Food Consumption and Body Weight

| Parameters | Sham | OVX |
|------------|------|-----|
|            | ND   | ND + GSM | HFHS | HFHS + GSM | ND   | ND + GSM | HFHS | HFHS + GSM | p   |
| BW 12th week | 273.73 ± 8.53 | 276.06 ± 6.20 | 280.84 ± 7.01 | 281.62 ± 7.54 | 275.64 ± 8.20 | 267.37 ± 8.96 | 276.51 ± 7.93 | 280.70 ± 6.41 | NS |
| BW 20th week | 317.30 ± 10.82<sup>abc</sup> | 325.39 ± 8.69<sup>abcd</sup> | 365.21 ± 12.28<sup>bcd</sup> | 380.91 ± 10.97<sup>c</sup> | 320.58 ± 7.72<sup>abc</sup> | 316.68 ± 11.37<sup>a</sup> | 372.09 ± 13.61<sup>de</sup> | 365.50 ± 11.78<sup>de</sup> | <0.001 |
| BW 28th week | 335.54 ± 12.40<sup>a</sup> | 349.75 ± 9.63<sup>ab</sup> | 397.77 ± 13.73<sup>b</sup> | 422.59 ± 12.54<sup>cde</sup> | 403.13 ± 11.05<sup>bcd</sup> | 394.58 ± 15.24<sup>abc</sup> | 470.91 ± 17.97<sup>a</sup> | 458.34 ± 14.92<sup>de</sup> | <0.001 |
| BW the end | 403.89 ± 17.30<sup>a</sup> | 428.18 ± 18.05<sup>b</sup> | 535.38 ± 27.16<sup>bc</sup> | 578.15 ± 21.78<sup>bc</sup> | 499.20 ± 18.56<sup>ab</sup> | 488.27 ± 22.36<sup>ab</sup> | 633.35 ± 34.01<sup>c</sup> | 619.05 ± 29.34<sup>c</sup> | <0.001 |
| Weight gain (g/d) | | | | | | | | | |
| Time 0 | 2.71 ± 0.11 | 2.85 ± 0.10 | 2.91 ± 0.09 | 2.93 ± 0.09 | 2.82 ± 0.09 | 2.65 ± 0.14 | 2.80 ± 0.10 | 2.85 ± 0.11 | NS |
| Time 1 | 0.65 ± 0.08<sup>a</sup> | 0.67 ± 0.08<sup>a</sup> | 0.99 ± 0.10<sup>ab</sup> | 1.37 ± 0.14<sup>b</sup> | 0.66 ± 0.07<sup>a</sup> | 0.70 ± 0.15<sup>a</sup> | 1.26 ± 0.20<sup>ab</sup> | 1.26 ± 0.27<sup>ab</sup> | <0.001 |
| Time 2 | 0.54 ± 0.05<sup>a</sup> | 0.56 ± 0.06<sup>a</sup> | 0.70 ± 0.09<sup>a</sup> | 0.69 ± 0.09<sup>a</sup> | 1.78 ± 0.10<sup>bc</sup> | 1.32 ± 0.10<sup>b</sup> | 1.74 ± 0.15<sup>bc</sup> | 1.89 ± 0.17<sup>c</sup> | <0.001 |
| Time 3 | 0.48 ± 0.05<sup>a</sup> | 0.55 ± 0.06<sup>a</sup> | 0.87 ± 0.10<sup>bcd</sup> | 0.94 ± 0.09<sup>c</sup> | 0.68 ± 0.07<sup>abc</sup> | 0.64 ± 0.05<sup>abc</sup> | 1.10 ± 0.14<sup>d</sup> | 1.06 ± 0.11<sup>d</sup> | <0.001 |
| Feed intake (g/d) | | | | | | | | | |
| Time 1 | 16.72 ± 0.53<sup>c</sup> | 15.90 ± 0.56<sup>bc</sup> | 12.71 ± 0.47<sup>a</sup> | 13.76 ± 0.37<sup>abc</sup> | 16.97 ± 0.51<sup>c</sup> | 15.55 ± 0.68<sup>bc</sup> | 13.28 ± 0.54<sup>a</sup> | 12.57 ± 0.41<sup>a</sup> | <0.001 |
| Time 2 | 16.17 ± 0.44<sup>b</sup> | 15.79 ± 0.56<sup>b</sup> | 11.94 ± 0.42<sup>a</sup> | 12.13 ± 0.38<sup>a</sup> | 19.53 ± 0.48<sup>c</sup> | 18.61 ± 0.62<sup>c</sup> | 14.76 ± 0.47<sup>b</sup> | 14.36 ± 0.48<sup>b</sup> | <0.001 |
| Time 3 | 16.19 ± 0.48<sup>b</sup> | 16.22 ± 0.53<sup>b</sup> | 12.86 ± 0.46<sup>a</sup> | 13.43 ± 0.43<sup>a</sup> | 16.81 ± 0.45<sup>b</sup> | 16.48 ± 0.37<sup>b</sup> | 13.61 ± 0.58<sup>a</sup> | 13.68 ± 0.49<sup>a</sup> | <0.001 |
| Energy intake (Kcal/d) | | | | | | | | | |
| Time 1 | 59.93 ± 1.91<sup>a</sup> | 57.00 ± 2.00<sup>a</sup> | 63.81 ± 2.38<sup>ab</sup> | 69.08 ± 1.84<sup>b</sup> | 60.82 ± 1.83<sup>ab</sup> | 55.75 ± 2.45<sup>a</sup> | 66.64 ± 2.71<sup>b</sup> | 63.08 ± 2.04<sup>ab</sup> | <0.001 |
| Time 2 | 57.96 ± 1.56<sup>ab</sup> | 56.60 ± 2.01<sup>a</sup> | 59.94 ± 2.11<sup>b</sup> | 60.89 ± 1.90<sup>a</sup> | 70.02 ± 1.71<sup>c</sup> | 66.71 ± 2.21<sup>bc</sup> | 74.07 ± 2.34<sup>c</sup> | 72.08 ± 2.39<sup>c</sup> | <0.001 |
| Time 3 | 58.03 ± 1.72<sup>a</sup> | 58.16 ± 1.88<sup>a</sup> | 64.54 ± 2.30<sup>bc</sup> | 67.39 ± 2.15<sup>bc</sup> | 60.27 ± 1.61<sup>abc</sup> | 59.09 ± 1.34<sup>a</sup> | 68.31 ± 2.90<sup>c</sup> | 68.65 ± 2.44<sup>c</sup> | <0.001 |

ND = normal control diet; HFHS = high-fat/high-sugar diet; OVX = ovariectomy; GSM = Greenshell mussel; BW = body weight. Time 0 = rat growing period on standard chow; Time 1 = experimental diets provided for 8 weeks; Time 2 = 8 weeks after the surgical procedure; Time 3 = termination of the study. The food consumption and body weight of different time points from the intact rats (sham) and the ovariectomized rats (OVX) in different diet groups are summarized. Values are mean ± SE. The significant differences across all conditions (diets and surgical procedures) were determined by one-way ANOVA and p values are indicated in the last column. In case no statistical significance (NS) was found, then no multiple comparison was performed. Significance is recognized when p < 0.05, and superscript letters indicate the least significant difference test. Values that do not share the same superscript letters are significantly different.
following periods (T1 to T3) declined consecutively, especially in intact rats on the normal control diet (ND), whereas BW gain in the OVX rats increased immediately after the surgical procedure (T2) before returning to the rate of gain observed in T1.

During the first 8 weeks on the experimental diets before surgery (T1), rats fed HFHS consumed 20% less food by weight than those fed ND but had a 12% higher kilojoule intake due to the HFHS diets being more energy-dense (Table 2). As a result, the
HFHS rats had an 82% higher rate of mean daily BW gain compared with ND rats. Inclusion of GSM during this period slightly increased weight gain, but this was not significant. After sham operation or OVX at the end of T1, during the next 8-week period (T2) feed intake, energy intake and BW gain were significantly higher in OVX rats compared with sham rats (BW gain in sham = 0.54 to 0.70 g/d versus OVX 1.32 to 1.89 g/d, \( p < 0.001 \)). For the last period of the study (T3), voluntary food consumption rate by OVX rats reduced to a similar rate as sham rats, but their BW gain continued to be higher than sham rats and subsequently OVX rats had higher BW at the end of the study, especially those fed HFHS. The OVX procedure increased total final BW by 24% and 18%, respectively, in rats fed ND and HFHS compared with their sham counterparts (\( p < 0.001 \)), but only 14% and 7%, respectively, in rats fed ND + GSM and HFHS + GSM, suggesting that regardless of diet type, the inclusion of GSM partially mitigated the weight gain caused by OVX, although this did not reach statistical significance.

### 3.3 Changes in body composition

In the long-term cohort (Fig. 2A), body fat mass of all rats increased significantly over time. Both HFHS and OVX independently caused significant increases in the acquisition of body fat mass. During T1 (ages 12 to 20 weeks), body fat mass approximately doubled in ND groups and tripled in HFHS groups. This increase was recapitulated during T2 after surgery (ages 20 to 28 weeks), and was even more pronounced during T3 (ages 28 to 48 weeks), when body fat mass increased nearly 10-fold; the effect was greatest in OVX rats fed HFHS. Interestingly, OVX
caused a significant increase in body lean mass over 8 weeks (T2), but no further gains in lean mass occurred during the 20-week T3 period. There was a significant interaction effect of diet and GSM on body lean mass. At T2, HFHS reduced the increase in lean mass acquired by ND rats. Adding GSM in ND caused a reduction in lean mass, whereas being combined with HFHS resulted in a slight increase in lean mass. However, the latter two findings were trends and did not reach statistical significance.

At the end of the short-term and long-term studies, all rats were subjected to necropsy and both visceral and subcutaneous fat pads were harvested and weighed (Fig. 2B). Data from the short-term cohort who did not undergo sham or OVX surgery were compared with the sham rats of the long-term cohort, whereas the OVX rats were compared against the sham rats in the same cohort. As expected, feeding HFHS diets to rats for 14 or 36 weeks resulted in a significant increase in retroperitoneal (32.84 ± 3.17) and perigonadal (21.52 ± 1.43) as well as inguinal (subcutaneous) white fat pad weights (17.76 ± 2.48) compared with ND but did not consistently alter the much smaller pad of interscapular brown fat (1.15 ± 0.08); the weight of the brown fat differed significantly only between the ND and HFHS + GSM groups in the short-term cohort and the long-term sham cohorts. Likewise, age significantly increased the weight of the white but not brown fat pads. OVX significantly increased the abdominal fat pads only in rats fed ND, but significantly increased the subcutaneous fat pad weight in all four diet groups. (Fig. 2B).

3.4 Changes in bone mineral density

Bone mineral density was measured in three different scans: whole body, lumbar spine, and right femur. In the short-term cohort (Fig. 3), whole-body BMD increased with time between baseline (age 12 weeks) to age 20 weeks (T1) and 26 weeks (T2) regardless of diet or GSM. Changes in BMD of spine and femurs were proportionally greater than whole-body.

![Fig 4. Percent change of bone mineral density in long-term cohort rats (12 to 48 weeks old). The individual chart represents bone mineral density (BMD) of the different bone sites, which are whole body (WB), lumbar spine (L1 to L4), and right femur. Bars and error bars represent means and SE (n = 12) of percent change between the baseline of bone mineral density (BMD) at week 12 and the particular time point (T1 or T2 or T3, which is week 20, 28, and 48, respectively). Repeated measure analysis was used to analyze statistically significant differences between the time points and those three effects (diet, GSM, and OVX). A sign (*) or # was labeled close to the name of the effects when statistical significance of the main effect was detected. The similar sign shown on different effects means the significance of the interaction effect between those. One-way ANOVA and least significant different methods were used to analyze data between groups within one particular time point, then differences of superscript letters show statistical significance. A table summary from repeated measures analysis shows p values, which is significant <0.05. ND = normal control diet; HFHS = high-fat/high-sugar diet; OVX = ovariectomy; GSM = Greenshell mussel.](image-url)
BMD. Of interest was the finding that inclusion of GSM in the HFHS diet significantly increased femur BMD during the final 6 weeks of the study (T2).

In the long-term cohort, OVX was the main determinant causing BMD to fail to increase in tandem with body mass; in particular, only OVX rats lost BMD in the lumbar spine and the right femur (Fig. 4). (FIG4) GSM showed a trend to increase whole-body, lumbar spine, and right femur BMD at T1 in all groups but ND sham rats, and a significant difference was also detected in sham rats on HFHS at T2 of the whole-body scan. There was an interaction effect between diet and surgical procedure in the lumbar spine BMD changes during T3. All sites of BMD in sham rats fed ND tended to be higher compared with sham HFHS rats, but the opposite effect was observed in OVX rats. Likewise, in the right femurs, only OVX had a significant effect, resulting in a significant reduction in BMD during T3.

3.5 Relationships between obesity and bone mineral density

To understand the relationship between obesity and BMD, data from T3 were interrogated and the correlations between BMD of individual bone sites and body weight, fat mass, lean mass, or leptin were graphed (Fig. 5). (FIG5) BW had minimal correlation with whole-body and right femur BMD at 0.280 and 0.268, respectively. Extracting BW into fat mass and lean mass resulted in a higher correlation of body lean mass with BMD in all scans, whereas body fat mass correlated poorly with BMD. Leptin, an adipokine produced by adipocytes, was highly correlated with fat mass (0.927, \( p < 0.001 \)) but showed no correlation with any BMD scans. Then BMD data were segregated into each group and correlation curves of BMD against BW or plasma leptin were depicted (Fig. 6 [FIG6] and Supplemental Fig. S6). As can be found in the graphs, there were tightly positive correlations between BMD and BW in only the sham rats on ND. Introducing other interventions of either GSM, HFHS, or OVX caused some modification of this pattern and possibly explained the interference of their effect on BMD. In the whole-body BMD, the positive correlation as shown by trend line turned downward in OVX rats on HFHS and similar downturns were also found in most groups of lumbar spine BMD.

3.6 Changes in plasma bone biomarkers

Bone metabolism was systematically altered by ovariectomy as can be found in the reduction of plasma TRAP (\( p = 0.036 \)) and
Fig 6. Correlation of body weight or leptin with bone mineral density in the individual group. Data at the final time point (T3) of the long-term cohort was stratified in the different condition groups and correlation analysis was performed. Correlation between body weight and bone mineral density (BMD) or between leptin and BMD is present in (A) and (B), respectively. The correlation table is provided in the Supplemental Material S1.

Fig 7. Changes in plasma bone markers. Plasma analysis was measured in the rats at 48 weeks of age. Bar graphs with error bars show means ± SE. Two-way ANOVA was used to evaluate the influence of effects of diet, surgical procedure, and GSM. If the effect was statistically significant, and asterisk (*) is indicated. A table summary from two-way ANOVA analysis shows p values that are significant at <0.05. ND = normal control diet; HFHS = high-fat/high-sugar diet; OVX = ovariectomy; GSM = Greenshell mussel.
4. Discussion

Our study showed that GSM supplementation increased BMD of the right femur, especially in rats in the short-term cohort. The statistically significant difference of this data is consistent even after adjusting BMD with BW. However, the effect was very mild (only 5% differences when compared with non-GSM diet), inconsistent with comparative BMD in other body sites, and transient as this effect disappeared at the same time (T2) and the later time (T3) in the long-term cohort. It is possible that with this very small effect size, a larger sample size would be needed to reveal a consistent result. On the other hand, it might be irrelevant to expect more than a minor change of BMD in physiologically normal rats as body homeostasis regulates the optimal levels of minerals in bone. Any values undergoing extreme changes may represent pathological stages rather than a beneficial effect. Another explanation is that a higher dose of bioactives may be required for efficacy; the dosage levels on a per-kg body weight basis would have been reduced as food intake did not proportionally increase with increased body weight.

In addition, the bioactives in GSM may not be potent enough to prevent severe bone loss from OVX. Our results seem to support the benefit of omega-3 rather than omega-6 because the composition of the diets supplemented with GSM contained DHA and EPA, whereas these omega-3 fatty acids were not present in the GSM-free diets. Arachidonic acid is an omega-6 fatty acid and was not present in any of the diet formulas. The total amount of DHA and EPA in ND + GSM was approximately 2 g/100 g. As the average daily feed intake of the rats was 20 g and the mean BW was 500 g, each rat would have received the combination of DHA and EPA at a dose of 800 mg/kg BW. This dose level is higher than the daily dosage recommended for humans(54,57) and reached the reported therapeutic doses of GSM in animal studies, although these studies did not specifically assess bone health. Thus, it would be predicted that the daily intake in the current study would at least maintain the effective dose of DHA and EPA for anti-inflammation in the rats. However, as individual lipids were not tested in this study, the bioactive factor(s) cannot be definitively identified. It is also noted that GSM diets contained more ash, and therefore it is possible that the beneficial effects of GSM included additive or synergistic effects between lipids, proteins and peptides, and/or minerals such as calcium.

Feeding rats with HFHS induced obesity, even though these animals consumed a lower volume of food because they had a higher overall energy intake due to the HFHS diet being energy-dense. This resulted in a greater rate of weight gain per day. Weight gain and BW increased in accordance with both feed intake and energy intake in all groups except the sham rats on ND + GSM. Although those rats consumed less food than their paired diet group and even though the GSM diets provided slightly lower energy source (fat, protein, and carbohydrate) the rats’ BW still increased significantly.

There was no significant change in the feed intake in all sham rats throughout the study. OVX rats, however, increased their food intake after the surgical procedure for a short period; within 2 months, their consumption rate reduced to these rats’ baseline intake and matched the same level as sham animals. The modified food intake in OVX rats had significant effects on their weight gain and increased body weight. This main effect resulted in OVX rats being the most obese in the study; the brief period of increased food intake is likely due to the fact that ovarian hormones have direct effects on adipose tissues and indirect effect on regulation of feed intake and energy expenditure via hypothalamus(43). Similar results were also found in other animal studies(44,45) and corresponding human studies in which postmenopausal women increased their food intake and weight a few years after the onset of menopause(46); alterations in metabolism that likely can be attributed to hormonal changes.

Fat mass was the source of BW gain in the older rats as can be found in the consecutive increase of percent change of body fat mass by DXA scans. Also, all main white fat pads harvested during necropsy (retroperitoneal, perigonadal, and inguinal fat pad) significantly increased from 6-month-old rats to 12-month-old rats. Inguinal fat, which is subcutaneous fat situated around groin and inguinal regions, was present as only a half of that perigonadal fat mass. In contrast to white fat, brown fat, a type of adipocyte responsible for utilizing energy expense through non-shivering thermogenesis, has an inverse relationship with body mass index in human. There was a significant increase of interscapular brown fat due to feeding HFHS diet, but this effect was not present in OVX rats. This conflicting data may not be due to the sole effect of estrogen deficiency but rather combined effects of the hormone and HFHS diet resulting in severely impaired insulin sensitivity, which was revealed by significantly increased Hba1c in the OVX rats fed HFHS diet in our previous report(48) and which influenced brown fat mass. Similar results of decreased brown fat mass were also revealed in obese male rats with insulin resistance(49). Moreover, insulin-deprived animal models and insulin knockout rodents model demonstrated a decrease in brown fat mass.(50)

As expected, HFHS and OVX obviously showed cumulative effects on the expansion of these fat pads; therefore, the OVX rats on HFHS accumulated more fat tissue compared with the other groups. Interestingly, the inguinal fat pad, a type of subcutaneous fat composed of mixed functional (white and brown) adipocytes in OVX rats accelerated its expansion more pronounced than retroperitoneal and perigonadal fat pad, which are visceral fat composed of white adipocytes. This revealed that OVX influenced shifting the course of fat accumulation from visceral fat to inguinal fat. OVX did not only influence fat deposition but also significantly increased lean mass in a short period of time after surgery. It is possible that the observed increase in food intake directly after ovariectomy supported an increase in body lean mass through increased protein intake. More importantly, the instant loss of estrogen due to ovariectomy would result in a higher androgen/estrogen ratio. The relative increase in androgens could enhance body lean mass and also influence the shift of fat distribution. This finding corroborates with Morita and colleagues(51) reporting a short-term increase of body lean mass in women after menopause and a shift of fat distribution from leg-groin area to the upper part of body and abdominal cavity. There was an interaction effect of diet and surgical procedure that could possibly explain the different effects of OVX on the significant increase of fat mass only in ND groups but not HFHS groups at T3. Body fat tended to increase in sham rats but reduced in OVX rats when adding GSM into the diets, although these differences did not reach statistical significance when compared by one-way ANOVA method within the same
time. In contrast, body lean mass increased and reached the peak at the middle age of the animals, then declined at the older age. Loss of BMD in OVX rats was observed consistently in the lumbar spine and femur scans. However, the whole-body scan, which is less accurate for detecting bone loss in obese subjects with high body fat compared with the other scans, did not show reduced BMD at the end of the study in OVX rats. Thus using the whole-body scan to interpret the relationship between body composition and BMD in the context of the obesity paradox may be inappropriate.

The other DXA scans revealed that the deposition of calcium in the femur, the long bone, takes precedence over the lumbar spine in rats as percent change of BMD in femur were higher compared with lumbar spine. Even though most bone sites showed significant bone loss in response to ovariectomy, the lumbar spine is the most sensitive bone site to detect the early bone loss in OVX rats. This finding seems to be different from the study of human trials indicating the total hip is the most reliable site for detecting osteoporosis or predicting hip fracture. This discrepancy might be due to the fact that our study scanned the whole femur, which is composed of more cortical bone rather than cancellous bone in the femoral head and pelvic part of the total hip region. However, the same study also recommended using spinal BMD for monitoring treatment. At around 6 months after OVX, estrogen deficiency could cause bone fragility in the lumbar spine as the BMD was lower than the baseline. The OVX rats fed HFHS lost BMD less than those fed ND in lumbar spine and right femur scans, indicating the benefit of obesity on reducing loss of BMD in OVX rats. It has been posited that the expansion of adipocytes in obesity may have an advantage on bone in postmenopausal women by being an alternative source of estrogen. Unfortunately, estrogen levels were not measured in this study and thus this cannot be confirmed, and a significant positive correlation between fat mass and BMD was not observed.

Bone health depends on the balance of bone metabolism, which is functioned by osteoblasts and osteoclasts. Many lines of evidence show that bone turnover rate (osteoclast function) increases after ovariectomy and results in bone loss. However, our study found that the bone turnover markers TRAP and CTX-I declined in the OVX rats. It is possible that adding HSHF diet in OVX rats could aggrerate hyperglycemia and insulin resistance in rats as mentioned before, resulting in the reduction of bone metabolism. This finding corroborates with evidence in human with type 2 diabetes who have reduced bone remodeling markers such as procollagen type 1 N-terminal propeptide, osteocalcin, alkaline phosphatase, and CTX-I. In addition, hyperglycemia mice induced by high-fat diet showed reduced biomechanical strength of trabecular and cortical bone with reduced expression of osteocalcin, as which the finding supported bone loss in hyperglycemia mice due to decreased bone formation (osteoblast function). Therefore, decreased bone metabolism is probably the underlying mechanism driving the reduction of BMD in our OVX rats. This finding reveals the fact that there may be different subtypes of osteoporosis in postmenopausal women based on the severity of metabolic conditions and, therefore, the specific therapeutic approach should be considered for those subtypes.

To explore some aspects of the complex relationship between obesity and bone and whether obesity has any benefit on BMD, relevant parameters of all rats at the endpoint data were pooled and correlation analysis was done. The data generally showed that it was not BW and fat mass but only lean mass that had a high correlation with BMD, although we observed significant correlations between fat mass and lean mass as well as between BW and fat mass and BW and lean mass. These findings demonstrate the complexity of defining “obesity” and might raise the question of whether BW needs to be adjusted for in correlation with BMD in obese populations as these subjects are likely to have increased fat mass proportionally higher than lean mass. High levels of fat mass correlated with increased leptin production in the rats, which in turn was highly correlated with BW and fat mass, but leptin still failed to show a correlation with BMD. The data were stratified into groups and the correlations were reevaluated. Surprisingly, a highly positive correlation of BW and BMD in ND/sham rats was detected in all bone site scans and a similar result was found in the correlation with leptin. Therefore, in our model, increased BW and leptin correlated with an observed positive influence on BMD within the normal weight range. We hypothesize that there are likely to be causal relationships between some of these parameters, but this has not yet been demonstrated.

Many findings in this animal study correspond with the evidence in postmenopausal women. In women, bone growth during childhood and adolescence contributes to the achievement of peak bone mass, resulting in bone strength of later life. Attainment of peak bone mass depends on a variety of nutritional and endocrine factors. Many studies have reported the benefits of polyunsaturated fat (PUFA) consumption; however, omega-3 and omega-6 are debated in context of anti-inflammation and bone health. The increase in BMD theoretically is related to increased calcium deposition in the bone matrix and this might be due to the capability of enhanced calcium absorption in duodenum by DHA and EPA.

However, some discrepancies between rodents and humans were evident in this study or have been reported elsewhere. For instance, women have two main parts of subcutaneous fat, all located at the lower part of the body, which is gluteofemoral and abdominal fat depot. Gluteofemoral fat in women has been considered as a healthy fat associated with lower triglycerides and higher concentration of high-density lipoprotein cholesterol, producing lower pro-inflammatory cytokines than visceral fat, whereas abdominal fat has detrimental effects associated with insulin sensitivity similar to visceral fat. A rat’s subcutaneous fat, on the other hand, is divided into cranial and caudal parts, which are intercapsular fat and inguinal fat, respectively. Both fat pads have common type of beige adipocytes and different from white adipocytes of visceral fat. In postmenopausal women, preferential site of fat deposition is shifted from subcutaneous fat depot to visceral fat depot (intra-abdominal fat) regardless of age, but this study showed that OVX rats increased inguinal fat mass more pronounced than visceral fat when compared with sham rats and, probably, total subcutaneous fat may be greater than visceral fat in OVX rats. Furthermore, women reach the peak of bone mass at the hip by approximately 20 years old followed by a decline, whereas rats are sexually mature by 2.5 months of age but bone growth still occurs until 10 months of age. BMD at all bone sites measured in the sham rats in this study increased over time; hence, the data may not extrapolate to human bone loss in advancing age. However, bone growth in this rat model provided an opportunity to investigate the effect of GSM on enhancement of calcium acquisition in bone.

In conclusion, our data have partially unraveled the ambiguity of the obesity paradox identified in humans and enabled
inference with human bone health by establishing correlations between a number of parameters. First, increased body weight appears to enhance BMD to some extent as long as the weight gain is associated with an increase in lean mass. High fat mass in general was not beneficial to bone density in these rats, although it has been reported to have some advantages of increased bone mass in postmenopausal women. Moreover, consumption of GSM was correlated with increased acquisition of BMD in younger rats but has no effect on increased BMD in ovarian hormone deficiency.

Acknowledgments

The authors thank Anne Broomfield (Massey University) for DXA scanning and Gabrielle Plimmer and De Shampa (Massey University) for support in necropsy. This study was funded by the National Science Challenge, High Value Nutrition (HVN) “Musseling up: high-value Greenshell mussel foods” (UOAX1421), MU College of Health PhD scholarship, as a collaboration between Massey University, Cawthron Institute, and Sanford Ltd.

Authors’ roles: Conceptualization: FMW, MCK, MRM, and HST. Methodology: FMW, MCK, and PS. Formal analysis: PS. Investigation: PS, MRM, and FMW. Resources: FMW and MCK. Data curation: PS. Writing—original draft preparation: PS. Writing—review and editing: FMW, MCK, MRM, HST, and PS. Visualization: PS. Supervision: FMW and MCK. Project administration: FMW. Funding acquisition: MRM, HST, and MCK.

References

1. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;103:185-199.
2. Zhao L-J, Jiang H, Papasian CJ, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res. 2008;23:17-29.
3. Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503:20-27.
4. Yang S, Shen X. Association and relative importance of multiple obesity measures with bone mineral density; the National Health and Nutrition Examination Survey 2005–2006. Arch Osteoporos. 2015; 10:14.
5. Sornay-Rendu E, Boutroy S, Vilayphiou N, Claustret B, Chapurlat RD. In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight: the Os des Femmes de Lyon (OFELY) study. J Bone Miner Res. 2013;28:1679-1687.
6. Evans AL, Paggiosi MA, Eastell R, Walsh JS. Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res. 2015;30:920-928.
7. De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330.
8. Tang X, Liu G, Kang J, et al. Obesity and risk of hip fracture in adults: a meta-analysis of prospective cohort studies. PLoS One. 2013;8(4):e55077.
9. Dimitri P, Bishop N, Walsh JS, Eastell R. Obesity is a risk factor for fracture in children but is protective against fracture in adults: a paradox. Bone. 2012;50(2):457-466.
10. Compston JE, Watts NB, Chapurlat R, et al. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011;124(11):1043-1050.
11. Prieto-Alhambra D, Pena-Morao MO, Fina Avilés F, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27(2):294-300.
12. Compston J. Obesity and fractures in postmenopausal women. Curr Opin Rheumatol. 2015;27(4):414-419.
13. Scott D, Daly RM, Sanders KM, Ebeling PR. Fall and fracture risk in sarcopenia and dynapenia with and without obesity: the role of lifestyle interventions. Curr Osteoporos Rep. 2015;13:235-244.
14. Scott D, Chandrasekara SD, Laslett LL, Cicuttini F, Ebeling PR, Jones G. Associations of sarcopenic obesity and dynapenic obesity with bone mineral density and incident fractures over 5–10 years in community-dwelling older adults. Calcif Tissue Int. 2016;99:30-42.
15. Fassio A, Idolazzi L, Rossini M, et al. The obesity paradox and osteoporosis. Eat Weight Disord. 2018;23(3):293-302.
16. Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009;122:409-414.
17. Xu F, Du Y, Hang S, Chen A, Guo F, Xu T. Adipocytes regulate the bone marrow microenvironment in a mouse model of obesity. Mol Med Rep. 2013;8:823-828.
18. Felson DT, Zhang Y, Hannan MT, Anderson JJ. Effects of weight and body mass index on bone mineral density in men and women: the Framingham Study. J Bone Miner Res. 1993;8:567-573.
19. Ravin P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wansch RD. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res. 1999;14:1622-1627.
20. Robling AG, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng. 2006;8:455-498.
21. Duan P, Bonewald LF. The role of the wnt/β-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol. 2016;77:23-29.
22. Thierry T, Francesca G, Sundeep K, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140(4):1630.
23. Stephan CM, Crawford DT, Chides-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in Ob/Ob mice. Regul Pept. 2000;92:73-78.
24. Burgueria B, Hofbauer LC, Thomas T, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinol Metab Clin N Am. 2001;20(2):346-353.
25. Gérard K, Mathieu F. The contribution of bone to whole-organism physiology. Nature. 2012;7381:314.
26. Wong IPL, Zengin A, Herzog H, Baldock PA. Central regulation of bone mass. Semin Cell Dev Biol. 2008;19(5):452-458.
27. Azamador-Llamas D, Hernandez-Molina G, Ramos-Avalos B, Furuzawa-Carballeda J. Adipokine contribution to the pathogenesis of osteoarthritis. Mediators Inflamm. 2017;2017:1-26.
28. Campos RM, de Piano A, da Silva PL, et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NALFD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine. 2012;42:146-156.
29. Collins KH, Reimer RA, Seerattan RA, Herzog W, Hart DA. Response to diet-induced obesity produces time-dependent induction and progression of metabolic osteoarthritis in rat knees. J Orthop Res. 2016;34(6):1010-1018.
30. Bolland MJ, Grey AB, Ames WR, Horne AM, Gamble GD, Reid IR. Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone. 2006;38(3):317-321.
31. Pitroda AP, Harris SS, Dawson-Hughes B. The association of adiposity with parathyroid hormone in healthy older adults. *Endocrine*. 2009;36(2):218.

32. Drincic AT, Armas LAG, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. *Obesity*. 2012;20:1444-1448.

33. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity [corrected] [published erratum appears in Am J Clin Nutr 2003 May;77(5):1342]. *Am J Clin Nutr*. 2000;72(3):690-693.

34. Treschkow AP, Hodges LD, Kalafatis N, Macrides TA, Wright PFA, Broadbent J. Anti-inflammatory activity of a lipid fraction (Lyprinol) from the NZ green-lipped mussel, *Perna canaliculus*. Inflammopharmacology. 1997;5(3):237-246.

35. McPhee S, Hodges LD, Wright PFA, et al. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, *Perna canaliculus*. *Comp Biochem Physiol B Biochem Mol Biol*. 2007;147(4):645-656.

36. Miller MR, Pearce L, Bettjeman B. Detailed distribution of lipids in Greenshell® mussel (*Perna canaliculus*). *Nutrients*. 2014;6(6):1454-1474.

37. Whitehouse MW, Macrides TA, Kalafatis N, Betts WH, Haynes DR, Broadbent J. Anti-inflammatory activity of a lipid fraction (Lyprinol) from the NZ green-lipped mussel. *Inflammopharmacology*. 1997;5(3):237-246.

38. Kruger MC, Schollum LM. Is docosahexaenoic acid more effective than eicosapentaenoic acid for increasing calcium bioavailability? *Prostaglandins Leukot Essent Fatty Acids*. 2005;73(3):327-334.

39. Kruger MC, Morel PCH. Experimental control for the ovariectomized rat model: use of sham versus nonmanipulated animal. *J Appl Anim Welf Sci*. 2016;19(1):73-80.

40. Siriarchavatana P, Kruger MC, Miller MR, Tian H, Wolber FM. Non-polar lipid from greenshell mussel (*Perna canaliculus*) inhibits osteoclast differentiation. *Bone Rep*. 2021;15:101132.

41. Punia S, Sandhu KS, Siroha AK, Dhull SB. Omega-3 metabolism, absorption, bioavailability and health benefits—a review. *PharmaNutrition*. 2019;10:100162.

42. Cooke PS, Naae A. Role of estrogens in adipocyte development and function. *Exp Biol Med*. 2004;229:1127-1135.

43. Rosaria M, Maria P, Giuseppina Mattace R, et al. Estrogen and relaxin-fene modulate leptin and its receptor in hypothalamic and adipose tissue from ovariectomized rats. *Endocrinology*. 2004;7:3115.

44. Roy EJ, Wade GN. Role of food intake in estradiol-induced body weight changes in female rats. *Horm Behav*. 1977;8(3):265-274.

45. Fonseca H, Powers SK, Gonäves D, Santos A, Mota MP, Duarte JA. Physical inactivity is a major contributor to ovariectomy-induced saropenia. *Int J Sports Med*. 2012;33(4):268-278.

46. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased high abdominal fat. The Health ABC Study. *Diabetes*. 2005;58(7):1526-1531.

47. Siriarchavatana P, Kruger MC, Miller MR, Tian H, Wolber FM. Effects of Greenshell mussel (*Perna canaliculus*) intake on pathological markers of multiple phenotypes of osteoarthritis in rats. *Appl Sci*. 2020;10(17):6131.

48. Pranprawit A, Wolber FM,Heyes J, Molan AL, Kruger MC. Short-term and long-term effects of excessive consumption of saturated fats and/or sucrose on metabolic variables in Sprague Dawley rats: a pilot study. *J Sci Food Agric*. 2013;93(13):3191-3197.

49. Maliszewska K, Kretowski A. Brown adipose tissue and its role in insulin and glucose homeostasis. *Int J Mol Sci*. 2021;22(4):1530.

50. Morita Y, Iwamoto I, Mizuma N, et al. Precedence of the shift of body-fat distribution over the change in body composition after menopause. *J Obstet Gynaecol Res*. 2006;32(5):513-516.

51. Sheu A, Diamond T. Bone mineral density: testing for osteoporosis. *Aust Prescr*. 2016;39(2):35-39.

52. Yoon K-H, Cho D-C, Yu S-H, Kim K-T, Jeon Y, Sung J-K. The change of bone metabolism in ovariectomized rats: analyses of eMкроCT scan and biochemical markers of bone turnover. *J Korean Neurosurg Soc*. 2012;51(6):323-327.

53. Tousen Y, Wolber FM, Chua WH, Tadaishi M, Ishimi Y, Kruger MC. Effects of daidzein and kiwifruit on bone mineral density and equal production in ovariectomised rats. *Int J Food Sci Nutr*. 2014;65(3):360-367.

54. Farr RN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. *J Bone Miner Res*. 2014;29(4):778-795.

55. Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. *Osteoporos Int*. 2012;23(2):635-641.

56. Iglesias P, Arrieta F, Piñera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. *Clin Endocrinol (Oxf)*. 2011;75(2):184-188.

57. Ross DS, Yeh T-H, King S, et al. Distinct effects of a high fat diet on bone in skeletal maturity and developing male C57BL/6J mice. *Nutrients*. 2021;13(5):1666.

58. Ho AYY, Kung AWC. Determinants of peak bone mineral density and bone area in young women. *J Bone Miner Metab*. 2005;23:470-475.

59. Whiting SJ, Vatanparast H, Baxter-Jones A, Faulkner RA, Mirmar R, Bailey DA. Factors that affect bone mineral accrual in the adolescent growth spurt. *J Nutr*. 2014;134:696-700.

60. Tortosa-Caparroés E, Marín F, Orenes-Piñero E, Navas-Carrillo D. Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. *Crit Rev Food Sci Nutr*. 2017;57(16):3421-3429.

61. Abdelhamid A, Hooper L, Sivakaran R, et al. The relationship between Omega-3, Omega-6 and total polyunsaturated fatty and musculoskeletal health and functional status in adults: a systematic review and meta-analysis of RCTs. *Calcif Tissue Int*. 2019;105(4):353-372.

62. Haag M, Magada ON, Claassen N, Böhmer LH, Kruger MC. Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption. *Prostaglandins Leukot Essent Fatty Acids*. 2003;68(6):423-428.

63. Snijder MB, Visser M, Dekker JM, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. *Diabetologia*. 2005;48(2):301.

64. Bos G, Snijder MB, Nijpels G, et al. Opposite contributions of trunk and leg fat mass with plasma lipase activities: the Hoorn study. *Obes Res*. 2005;13:1817-1823.

65. Manolopoulos KN, Karpe F, Fryn KN. Gluteofemoral body fat as a determinant of metabolic health. *Int J Obes*. 2010;34:999-959.

66. Kelley DE, Thaete FL, Troost F, Huve T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. *Am J Physiol Endocrinol Metab*. 2000;278:E941-E948.

67. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. *Metab Clin Exp*. 2001;50:425-435.

68. Toth MJ, Tschernow A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. *Ann N Y Acad Sci*. 2000;904:502-506.

69. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an animal model for osteoporosis research. *Comp Med*. 2008;58(5):424-430.